A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Active, not recruiting · Phase 1 · NCT05259839
Conditions: Relapsed/Refractory Multiple Myeloma
At a glance
- Research payments reported, 2025
- $1.4M
- U.S. investigators named
- 14
- Sites paid
- 14
- Planned or actual enrollment
- 283
About the trial
- Sponsor
- AbbVie
- Tested
- Etentamig (drug), Dexamethasone (drug), Lenalidomide (drug), Pomalidomide (drug), Daratumumab (drug)
- Dates
- Started 2022-10-20; completion 2033-09
- Results posted
- Not yet
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatm…
From ClinicalTrials.gov, last updated 2026-08-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.4M in research payments for this study in 2025 (75 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Frits Van Rhee, MD Hematology & Oncology · Little Rock, AR
- Ariel F. Grajales-cruz Hematology & Oncology · Tampa, FL
- Dickran G. Kazandjian, M.D. Hematology & Oncology · Miami, FL
- Shonali Midha, M.D. Hematology · Boston, MA
- Muthalagu Ramanathan, MD Hematology & Oncology · Worcester, MA
- Matthew J. Pianko, M.D. Hematology · Ann Arbor, MI
- Peter M. Voorhees, MD Hematology · Charlotte, NC
- Jason Suh, M.D. Hematology & Oncology · Paramus, NJ
- Malin Hultcrantz, MD PHD Hematology & Oncology · New York, NY
- Cesar Rodriguez Valdes, M.D. Medical Oncology · New York, NY
- Larry D. Anderson JR., M.D. , PHD Medical Oncology · Dallas, TX
- Amandeep Godara, MD Hematology & Oncology · Salt Lake City, UT
- Andrew J. Cowan, M.D. Hematology & Oncology · Seattle, WA
- Anita D'souza, MD Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Biomedical Research Alliance Of $393,552
- University of Michigan Health System, MI $164,139
- Dana Farbermass General Brigham $124,088
- The University of Texas $115,157
- University of Miami $111,488
- University of Utah Hospital and Clinics, UT $106,239
- Moffitt Cancer Center $97,369
- Medical College of Wisconsin $86,364
- Carolinas Medical Center-Northeast, NC $63,693
- The Valley Hospital Inc $38,634
- University of Arkansas Medical Sciences, AR $26,291
- Memorial Sloan-Kettering Cancer Ctr $22,596
- University of Washington Medical Ctr, WA $15,856
- University of Massachusetts $1,240
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.